Effective cancer therapy usually requires the assistance of well-designed drug carriers. In order to increase the drug accumulation to tumor tissue as well as to reduce the side effects of drug carriers, the hybrid drug delivery system (DDS) was developed by integrating folic acid (FA) and a metal-organic framework (MOF). The anticancer drug doxorubicin (DOX) was preloaded into the MOF nanoparticles during the synthesis process of the MOF nanoparticles. After surface modification with FA, the resulting FA/MOF/DOX nanoparticles were capable of serving as a biocompatible osteosarcoma targeting a DDS to enhance the chemotherapy of osteosarcoma. The dynamic light scattering method revealed that the obtained FA/MOF/DOX nanoparticles were particles with a size around 100 nm. Moreover, FA/MOF/DOX nanoparticles could enhance the delivery efficacy of DOX into MG63 (human osteosarcoma) cells as compared to FA free nanoparticles (MOF/DOX), in which a folate receptor (FR) might be involved. It was worth mentioning that in vitro [methylthio tetrazole (MTT) study in the MG63 cells] and in vivo (anticancer study in the MG63 xenograft model) assays both revealed that FA/MOF/DOX nanoparticles possessed stronger anticancer capability than free DOX or MOF/DOX nanoparticles.

中文翻译：

---

叶酸修饰的金属-有机骨架装有阿霉素，可用于肿瘤靶向的骨肉瘤化疗。

有效的癌症治疗通常需要精心设计的药物载体的协助。为了增加药物向肿瘤组织的蓄积并减少药物载体的副作用，通过整合叶酸（FA）和金属有机骨架（MOF）开发了混合药物递送系统（DDS）。在MOF纳米颗粒的合成过程中，将抗癌药阿霉素（DOX）预装到MOF纳米颗粒中。用FA进行表面修饰后，所得的FA / MOF / DOX纳米颗粒能够用作靶向DDS的生物相容性骨肉瘤，以增强骨肉瘤的化学疗法。动态光散射法显示，所获得的FA / MOF / DOX纳米颗粒是尺寸为约100nm的颗粒。此外，与可能涉及叶酸受体（FR）的不含FA的纳米颗粒（MOF / DOX）相比，FA / MOF / DOX纳米颗粒可以增强DOX进入MG63（人骨肉瘤）细胞的递送功效。值得一提的是体外[在MG63细胞中进行甲硫基四唑（MTT）研究]和体内（在MG63异种移植模型中进行抗癌研究）试验均显示，FA / MOF / DOX纳米粒比游离DOX或MOF / DOX纳米粒具有更强的抗癌能力。